Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients

• Status: Active, not recruiting
• Trial end date: 2022-02-01

Summary

Melatonin may represent an effective complementary treatment to standard anticancer treatments in order to reduce asthenia, depression, sleep disturbances, cognitive impairment and performance status as part of quality of life. Moreover, melatonin has been evaluated in several clinical trials in cancer patients with no side effects. It could be particularly of interest in elderly cancer patients as they exhibit a significant deficiency of melatonin production .

The investigators propose to perform a prospective and randomized study to study the effect of a melatonin supplementation on the quality of life of elderly advanced/metastatic cancer patients (age ≥ 70) treated for a locally advanced or metastatic cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Centre Jean Perrin
• Treatments: Melatonin